Merck CEO on Winrevair Approval, Obesity Drug, Health Costs

Merck Chair and CEO Robert M. Davis discusses the US approval of Winrevair, a new treatment for a rare, dangerous form of high blood pressure. Speaking on Bloomberg Television, Davis also comments on Merck's development of an obesity-fighting drug and health-care costs.
For more on this story, please see: www.bloomberg....

[@carlettagoodrich-mann1377]

As a retired employee for MERCK congratulations

[@carlettagoodrich-mann1377]

Mark moving into cardio metabolic space sounds like you’re being on the cutting edge for our new development. Congratulations. How do I get my stock options?

[@yml84]

Interesting how Bloomberg used the wrong still for the video tile, it shows the Merck KGaA building and logo and this is Merck &Co, known as MSD ex-US.

[@carlettagoodrich-mann1377]

Remember the patient FIRST. OUTCOME darabases must be proven evidence’s clearly monitored with safety guidelines.

[@AmitKumar-tg7of]

Lies, damned lies and statistics

[@amdhosni]

Overcafeinated interviewers. No need to shout. Less coffee please!